Publications 2024

Foote JB, Mattox TE, Keeton AB, Chen X, Smith FT, Berry KL, Holmes T, Wang J, Huang CH, Ward AB, Hardy C, Fleten KG, Flatmark K, Yoon KJ, Sarvesh S, Ganji PN, Maxuitenko Y, Valiyaveettil J, Carstens JL, Buchsbaum DJ, Yang J, Zhou G, Nurmemmedov E, Babic I, Gaponenko V et al. (2024)
A Novel Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth in Mouse Models of GI Cancer
bioRxiv
DOI 10.1101/2023.05.17.541233, PubMed 38328254

Publications 2023

Arjona-Sanchez A, Martinez-López A, Moreno-Montilla MT, Mulsow J, Lozano-Lominchar P, Martínez-Torres B, Rau B, Canbay E, Sommariva A, Milione M, Deraco M, Sgarbura O, Torgunrud A, Kepenekian V, Carr NJ, Hoorens A, Delhorme JB, Wernert R, Goere D, Martin-Roman L, Cosyns S, Flatmark K, Davidson B, Khellaf L, Pereira-Perez F et al. (2023)
External multicentre validation of pseudomyxoma peritonei PSOGI-Ki67 classification
Eur J Surg Oncol, 49 (8), 1481-1488
DOI 10.1016/j.ejso.2023.03.206, PubMed 36935222

Hyldbakk A, Fleten KG, Snipstad S, Åslund AKO, Davies CL, Flatmark K, Mørch Y (2023)
Intraperitoneal administration of cabazitaxel-loaded nanoparticles in peritoneal metastasis models
Nanomedicine, 48, 102656
DOI 10.1016/j.nano.2023.102656, PubMed 36646195

Ito I, Yousef AM, Dickson PN, Naini ZA, White MG, Fleten KG, Flatmark K, Fournier KF, Fowlkes NW, Shen JP (2023)
Antitumor activity of intraperitoneal paclitaxel in orthotopic patient-derived xenograft models of mucinous appendiceal adenocarcinoma
bioRxiv
DOI 10.1101/2023.02.01.526672, PubMed 36993681

Ito I, Yousef AMG, Chowdhury S, Dickson PN, Naini ZA, White MG, Fleten KG, Flatmark K, Fournier KF, Fowlkes NW, Shen JP (2023)
Intraperitoneal Paclitaxel Is a Safe and Effective Therapeutic Strategy for Treating Mucinous Appendiceal Adenocarcinoma
Cancer Res, 83 (19), 3184-3191
DOI 10.1158/0008-5472.CAN-23-0013, PubMed 37433032

Nygaard V, Ree AH, Dagenborg VJ, Børresen-Dale AL, Edwin B, Fretland ÅA, Grzyb K, Haugen MH, Mælandsmo GM, Flatmark K (2023)
A PRRX1 Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver Metastases
Cancer Res Commun, 3 (2), 235-244
DOI 10.1158/2767-9764.CRC-22-0295, PubMed 36968142

Patrick-Brown TDJH, Mohamed F, Thrower A, Torgunrud A, Cosyns S, Canbay E, Villeneuve L, Flatmark K, Brandl A (2023)
Determining a minimum data set for reporting clinical and radiologic data for pseudomyxoma peritonei
Pleura Peritoneum, 8 (1), 1-9
DOI 10.1515/pp-2022-0200, PubMed 37020469

Solbakken AM, Flatmark K (2023)
ASO Author Reflections: Navigation-Assisted Surgery for Locally Advanced and Recurrent Rectal Cancer: The NAVI-LARRC Trial
Ann Surg Oncol, 30 (12), 7633-7634
DOI 10.1245/s10434-023-14058-2, PubMed 37573284

Solbakken AM, Sellevold S, Spasojevic M, Julsrud L, Emblemsvåg HL, Reims HM, Sørensen O, Thorgersen EB, Fauske L, Ågren JSM, Brennhovd B, Ryder T, Larsen SG, Flatmark K (2023)
Navigation-Assisted Surgery for Locally Advanced Primary and Recurrent Rectal Cancer
Ann Surg Oncol, 30 (12), 7602-7611
DOI 10.1245/s10434-023-13964-9, PubMed 37481493

Thorgersen EB, Solbakken AM, Strøm TK, Goscinski M, Spasojevic M, Larsen SG, Flatmark K (2023)
Short-term results after robot-assisted surgery for primary rectal cancers requiring beyond total mesorectal excision in multiple compartments
Scand J Surg, 113 (1), 3-12
DOI 10.1177/14574969231200654, PubMed 37787437

Publications 2022

Ambrosini M, Del Re M, Manca P, Hendifar A, Drilon A, Harada G, Ree AH, Klempner S, Mælandsmo GM, Flatmark K, Russnes HG, Cleary JM, Singh H, Sottotetti E, Martinetti A, Randon G, Sartore-Bianchi A, Capone I, Milione M, Di Bartolomeo M, Pietrantonio F (2022)
ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series
JCO Precis Oncol, 6 (1), e2200015
DOI 10.1200/PO.22.00015, PubMed 35476549

Fleten KG, Hyldbakk A, Einen C, Benjakul S, Strand BL, Davies CL, Mørch Ý, Flatmark K (2022)
Alginate Microsphere Encapsulation of Drug-Loaded Nanoparticles: A Novel Strategy for Intraperitoneal Drug Delivery
Mar Drugs, 20 (12)
DOI 10.3390/md20120744, PubMed 36547891

Fusser M, Øverbye A, Pandya AD, Mørch Ý, Borgos SE, Kildal W, Snipstad S, Sulheim E, Fleten KG, Askautrud HA, Engebraaten O, Flatmark K, Iversen TG, Sandvig K, Skotland T, Mælandsmo GM (2022)
Corrigendum to "Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft", [Journal of Control Release, 293 (2019) 183-192]
J Control Release, 349, 1
DOI 10.1016/j.jconrel.2022.06.040, PubMed 35792388

Høye E, Dagenborg VJ, Torgunrud A, Lund-Andersen C, Fretland ÅA, Lorenz S, Edwin B, Hovig E, Fromm B, Inderberg EM, Greiff V, Ree AH, Flatmark K (2022)
T cell receptor repertoire sequencing reveals chemotherapy-driven clonal expansion in colorectal liver metastases
Gigascience, 12
DOI 10.1093/gigascience/giad032, PubMed 37161965

Høye E, Fromm B, Böttger PHM, Domanska D, Torgunrud A, Lund-Andersen C, Abrahamsen TW, Fretland ÅA, Dagenborg VJ, Lorenz S, Edwin B, Hovig E, Flatmark K (2022)
A comprehensive framework for analysis of microRNA sequencing data in metastatic colorectal cancer
NAR Cancer, 4 (1), zcab051
DOI 10.1093/narcan/zcab051, PubMed 35047825

Meltzer S, Negård A, Bakke KM, Hamre HM, Kersten C, Hofsli E, Guren MG, Sorbye H, Flatmark K, Ree AH (2022)
Early radiologic signal of responsiveness to immune checkpoint blockade in microsatellite-stable/mismatch repair-proficient metastatic colorectal cancer
Br J Cancer, 127 (12), 2227-2233
DOI 10.1038/s41416-022-02004-0, PubMed 36229579

Ree AH, Mælandsmo GM, Flatmark K, Russnes HG, Gómez Castañeda M, Aas E (2022)
Cost-effectiveness of molecularly matched off-label therapies for end-stage cancer - the MetAction precision medicine study
Acta Oncol, 61 (8), 955-962
DOI 10.1080/0284186X.2022.2098053, PubMed 35943168

Publications 2021

Andersson Y, Fleten KG, Abrahamsen TW, Reed W, Davidson B, Flatmark K (2021)
Anti-Angiogenic Treatment in Pseudomyxoma Peritonei-Still a Strong Preclinical Rationale
Cancers (Basel), 13 (11)
DOI 10.3390/cancers13112819, PubMed 34198773

Dagenborg VJ, Marshall SE, Grzyb K, Fretland ÅA, Lund-Iversen M, Mælandsmo GM, Ree AH, Edwin B, Yaqub S, Flatmark K (2021)
Low Concordance Between T-Cell Densities in Matched Primary Tumors and Liver Metastases in Microsatellite Stable Colorectal Cancer
Front Oncol, 11, 671629
DOI 10.3389/fonc.2021.671629, PubMed 34178659

Flatmark K, Torgunrud A, Fleten KG, Davidson B, Juul HV, Mensali N, Lund-Andersen C, Inderberg EM (2021)
Peptide vaccine targeting mutated GNAS: a potential novel treatment for pseudomyxoma peritonei
J Immunother Cancer, 9 (10)
DOI 10.1136/jitc-2021-003109, PubMed 34711663

Fleten KG, Eksteen JJ, Mauseth B, Camilio KA, Vasskog T, Sveinbjørnsson B, Rekdal Ø, Mælandsmo GM, Flatmark K (2021)
Oncolytic peptides DTT-205 and DTT-304 induce complete regression and protective immune response in experimental murine colorectal cancer
Sci Rep, 11 (1), 6731
DOI 10.1038/s41598-021-86239-6, PubMed 33762676

Knuth F, Adde IA, Huynh BN, Groendahl AR, Winter RM, Negård A, Holmedal SH, Meltzer S, Ree AH, Flatmark K, Dueland S, Hole KH, Seierstad T, Redalen KR, Futsaether CM (2021)
MRI-based automatic segmentation of rectal cancer using 2D U-Net on two independent cohorts
Acta Oncol, 61 (2), 255-263
DOI 10.1080/0284186X.2021.2013530, PubMed 34918621

Larsen SG, Goscinski MA, Dueland S, Steigen SE, Hofsli E, Torgunrud A, Lund-Iversen M, Dagenborg VJ, Flatmark K, Sorbye H (2021)
Impact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients
Br J Cancer, 126 (5), 726-735
DOI 10.1038/s41416-021-01620-6, PubMed 34887523

Lund-Andersen C, Torgunrud A, Fleten KG, Flatmark K (2021)
Omics analyses in peritoneal metastasis-utility in the management of peritoneal metastases from colorectal cancer and pseudomyxoma peritonei: a narrative review
J Gastrointest Oncol, 12 (Suppl 1), S191-S203
DOI 10.21037/jgo-20-136, PubMed 33968437

Mariathasan AB, Boye K, Dueland S, Flatmark K, Larsen SG (2021)
Metastases in locally advanced rectal cancer undergoing curatively intended treatment
Eur J Surg Oncol, 47 (9), 2377-2383
DOI 10.1016/j.ejso.2021.04.023, PubMed 34049768

Meltzer S, Torgunrud A, Abrahamsson H, Solbakken AM, Flatmark K, Dueland S, Bakke KM, Bousquet PA, Negård A, Johansen C, Lyckander LG, Larsen FO, Schou JV, Redalen KR, Ree AH (2021)
The circulating soluble form of the CD40 costimulatory immune checkpoint receptor and liver metastasis risk in rectal cancer
Br J Cancer, 125 (2), 240-246
DOI 10.1038/s41416-021-01377-y, PubMed 33837301

Sørensen O, Andersen AM, Larsen SG, Giercksky KE, Flatmark K (2021)
Correction to: Intraperitoneal mitomycin C improves survival compared to cytoreductive surgery alone in an experimental model of highgrade pseudomyxoma peritonei
Clin Exp Metastasis, 38 (2), 253
DOI 10.1007/s10585-021-10084-0, PubMed 33649933

Thorgersen EB, Asvall J, Frøysnes IS, Schjalm C, Larsen SG, Dueland S, Andersson Y, Fodstad Ø, Mollnes TE, Flatmark K (2021)
Increased Local Inflammatory Response to MOC31PE Immunotoxin After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Ann Surg Oncol, 28 (9), 5252-5262
DOI 10.1245/s10434-021-10022-0, PubMed 34019185

Thorgersen EB, Flatmark K (2021)
ASO Author Reflections: The Peritoneum is an Active Immunological Compartment
Ann Surg Oncol, 28 (9), 5263-5264
DOI 10.1245/s10434-021-10036-8, PubMed 33939046

Publications 2020

Aghayan DL, Kazaryan AM, Dagenborg VJ, Røsok BI, Fagerland MW, Waaler Bjørnelv GM, Kristiansen R, Flatmark K, Fretland ÅA, Edwin B, OSLO-COMET Survival Study Collaborators (2020)
Long-Term Oncologic Outcomes After Laparoscopic Versus Open Resection for Colorectal Liver Metastases : A Randomized Trial
Ann Intern Med, 174 (2), 175-182
DOI 10.7326/M20-4011, PubMed 33197213

Dagenborg VJ, Marshall SE, Yaqub S, Grzyb K, Boye K, Lund-Iversen M, Høye E, Berstad AE, Fretland ÅA, Edwin B, Ree AH, Flatmark K (2020)
Neoadjuvant chemotherapy is associated with a transient increase of intratumoral T-cell density in microsatellite stable colorectal liver metastases
Cancer Biol Ther, 21 (5), 432-440
DOI 10.1080/15384047.2020.1721252, PubMed 32098573

Flatmark K, Mohamed F (2020)
ASO Author Reflections: Estimating the Prevalence of Pseudomyxoma Peritonei in Europe Using a Novel Statistical Method
Ann Surg Oncol, 27 (Suppl 3), 771-772
DOI 10.1245/s10434-020-08691-4, PubMed 32495284

Fleten KG, Lund-Andersen C, Waagene S, Abrahamsen TW, Mørch Y, Boye K, Torgunrud A, Flatmark K (2020)
Experimental Treatment of Mucinous Peritoneal Metastases Using Patient-Derived Xenograft Models
Transl Oncol, 13 (8), 100793
DOI 10.1016/j.tranon.2020.100793, PubMed 32447231

Fromm B, Domanska D, Høye E, Ovchinnikov V, Kang W, Aparicio-Puerta E, Johansen M, Flatmark K, Mathelier A, Hovig E, Hackenberg M, Friedländer MR, Peterson KJ (2020)
MirGeneDB 2.0: the metazoan microRNA complement
Nucleic Acids Res, 48 (D1), D132-D141
DOI 10.1093/nar/gkz885, PubMed 31598695

Fromm B, Domanska D, Høye E, Ovchinnikov V, Kang W, Aparicio-Puerta E, Johansen M, Flatmark K, Mathelier A, Hovig E, Hackenberg M, Friedländer MR, Peterson KJ (2020)
MirGeneDB 2.0: the metazoan microRNA complement
Nucleic Acids Res, 48 (D1), D1172
DOI 10.1093/nar/gkz1016, PubMed 31642479

Meltzer S, Bjørnetrø T, Lyckander LG, Flatmark K, Dueland S, Samiappan R, Johansen C, Kalanxhi E, Ree AH, Redalen KR (2020)
Corrigendum to "Circulating Exosomal miR-141-3p and miR-375 in Metastatic Progression of Rectal Cancer" [Transl Oncol 12 (8) (2019) 1038-1044]
Transl Oncol, 13 (1), 122-124
DOI 10.1016/j.tranon.2019.09.005, PubMed 31843135

Patrick-Brown TDJH, Carr NJ, Swanson DM, Larsen S, Mohamed F, Flatmark K (2020)
Estimating the Prevalence of Pseudomyxoma Peritonei in Europe Using a Novel Statistical Method
Ann Surg Oncol, 28 (1), 252-257
DOI 10.1245/s10434-020-08655-8, PubMed 32488520

Ree AH, Nygaard V, Boye K, Heinrich D, Dueland S, Bergheim IR, Johansen C, Beiske K, Negård A, Lund-Iversen M, Nygaard V, Hovig E, Nakken S, Nasser S, Julsrud L, Reisse CH, Ruud EA, Kristensen VN, Flørenes VA, Geitvik GA, Lingjærde OC, Børresen-Dale AL, Russnes HG, Mælandsmo GM, Flatmark K (2020)
Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer - the MetAction study
Acta Oncol, 59 (7), 733-740
DOI 10.1080/0284186X.2020.1742377, PubMed 32208873

Publications 2019

Abrahamsson H, Porojnicu AC, Lindstrøm JC, Dueland S, Flatmark K, Hole KH, Seierstad T, Moan J, Redalen KR, Meltzer S, Ree AH (2019)
High level of circulating vitamin D during neoadjuvant therapy may lower risk of metastatic progression in high-risk rectal cancer
BMC Cancer, 19 (1), 488
DOI 10.1186/s12885-019-5724-z, PubMed 31122213

Aghayan DL, Fretland ÅA, Kazaryan AM, Sahakyan MA, Dagenborg VJ, Bjørnbeth BA, Flatmark K, Kristiansen R, Edwin B (2019)
Laparoscopic versus open liver resection in the posterosuperior segments: a sub-group analysis from the OSLO-COMET randomized controlled trial
HPB (Oxford), 21 (11), 1485-1490
DOI 10.1016/j.hpb.2019.03.358, PubMed 30962136

Andersson Y, Inderberg EM, Kvalheim G, Herud TM, Engebraaten O, Flatmark K, Dueland S, Fodstad Ø (2019)
Immune stimulatory effect of anti-EpCAM immunotoxin - improved overall survival of metastatic colorectal cancer patients
Acta Oncol, 59 (4), 404-409
DOI 10.1080/0284186X.2019.1704864, PubMed 31876430

Bains SJ, Abrahamsson H, Flatmark K, Dueland S, Hole KH, Seierstad T, Redalen KR, Meltzer S, Ree AH (2019)
Immunogenic cell death by neoadjuvant oxaliplatin and radiation protects against metastatic failure in high-risk rectal cancer
Cancer Immunol Immunother, 69 (3), 355-364
DOI 10.1007/s00262-019-02458-x, PubMed 31893287

Flørenes VA, Flem-Karlsen K, McFadden E, Bergheim IR, Nygaard V, Nygård V, Farstad IN, Øy GF, Emilsen E, Giller-Fleten K, Ree AH, Flatmark K, Gullestad HP, Hermann R, Ryder T, Wernhoff P, Mælandsmo GM (2019)
A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases
Transl Oncol, 12 (7), 951-958
DOI 10.1016/j.tranon.2019.04.001, PubMed 31096111

Frøysnes IS, Andersson Y, Larsen SG, Davidson B, Øien JT, Julsrud L, Fodstad Ø, Dueland S, Flatmark K (2019)
ImmunoPeCa trial: Long-term outcome following intraperitoneal MOC31PE immunotoxin treatment in colorectal peritoneal metastasis
Eur J Surg Oncol, 47 (1), 134-138
DOI 10.1016/j.ejso.2019.04.014, PubMed 31036394

Lund-Andersen C, Nakken S, Nygård S, Fromm B, Aasheim LB, Davidson B, Julsrud L, Abrahamsen TW, Kristensen AT, Dybdahl B, Larsen SG, Hovig E, Flatmark K (2019)
Integrative genomic analysis of peritoneal malignant mesothelioma: understanding a case with extraordinary chemotherapy response
Cold Spring Harb Mol Case Stud, 5 (2)
DOI 10.1101/mcs.a003566, PubMed 30862609

Meltzer S, Bakke KM, Rød KL, Negård A, Flatmark K, Solbakken AM, Kristensen AT, Fuglestad AJ, Kersten C, Dueland S, Seierstad T, Hole KH, Lyckander LG, Larsen FO, Schou JV, Patrick Brown D, Abrahamsson H, Redalen KR, Ree AH (2019)
Sex-related differences in primary metastatic site in rectal cancer; associated with hemodynamic factors?
Clin Transl Radiat Oncol, 21, 5-10
DOI 10.1016/j.ctro.2019.11.006, PubMed 31872084

Meltzer S, Bjørnetrø T, Lyckander LG, Flatmark K, Dueland S, Samiappan R, Johansen C, Kalanxhi E, Ree AH, Redalen KR (2019)
Circulating Exosomal miR-141-3p and miR-375 in Metastatic Progression of Rectal Cancer
Transl Oncol, 12 (8), 1038-1044
DOI 10.1016/j.tranon.2019.04.014, PubMed 31146167

Ree AH, Nygaard V, Russnes HG, Heinrich D, Nygaard V, Johansen C, Bergheim IR, Hovig E, Beiske K, Negård A, Børresen-Dale AL, Flatmark K, Mælandsmo GM (2019)
Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain
Cancer Immunol Res, 7 (5), 701-706
DOI 10.1158/2326-6066.CIR-18-0777, PubMed 30804006

Sørensen O, Andersen AM, Larsen SG, Giercksky KE, Flatmark K (2019)
Intraperitoneal mitomycin C improves survival compared to cytoreductive surgery alone in an experimental model of high-grade pseudomyxoma peritonei
Clin Exp Metastasis, 36 (6), 511-518
DOI 10.1007/s10585-019-09991-0, PubMed 31541325

Publications 2018

Bousquet PA, Meltzer S, Sønstevold L, Esbensen Y, Dueland S, Flatmark K, Sitter B, Bathen TF, Seierstad T, Redalen KR, Eide L, Ree AH (2018)
Markers of Mitochondrial Metabolism in Tumor Hypoxia, Systemic Inflammation, and Adverse Outcome of Rectal Cancer
Transl Oncol, 12 (1), 76-83
DOI 10.1016/j.tranon.2018.09.010, PubMed 30273860

Fretland ÅA, Dagenborg VJ, Bjørnelv GMW, Kazaryan AM, Kristiansen R, Fagerland MW, Hausken J, Tønnessen TI, Abildgaard A, Barkhatov L, Yaqub S, Røsok BI, Bjørnbeth BA, Andersen MH, Flatmark K, Aas E, Edwin B (2018)
Laparoscopic Versus Open Resection for Colorectal Liver Metastases: The OSLO-COMET Randomized Controlled Trial
Ann Surg, 267 (2), 199-207
DOI 10.1097/SLA.0000000000002353, PubMed 28657937

Fusser M, Øverbye A, Pandya AD, Mørch Ý, Borgos SE, Kildal W, Snipstad S, Sulheim E, Fleten KG, Askautrud HA, Engebraaten O, Flatmark K, Iversen TG, Sandvig K, Skotland T, Mælandsmo GM (2018)
Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft
J Control Release, 293, 183-192
DOI 10.1016/j.jconrel.2018.11.029, PubMed 30529259

Kalanxhi E, Meltzer S, Schou JV, Larsen FO, Dueland S, Flatmark K, Jensen BV, Hole KH, Seierstad T, Redalen KR, Nielsen DL, Ree AH (2018)
Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer
Br J Cancer, 118 (10), 1322-1328
DOI 10.1038/s41416-018-0085-y, PubMed 29695770

Mariathasan AB, Boye K, Giercksky KE, Brennhovd B, Gullestad HP, Emblemsvåg HL, Grøholt KK, Dueland S, Flatmark K, Larsen SG (2018)
Beyond total mesorectal excision in locally advanced rectal cancer with organ or pelvic side-wall involvement
Eur J Surg Oncol, 44 (8), 1226-1232
DOI 10.1016/j.ejso.2018.03.029, PubMed 29691115

Mikalsen SG, Mikalsen LTG, Sandvik JA, Aarnes EK, Fenne S, Flatmark K, Lyng H, Edin NFJ, Pettersen EO (2018)
Low dose-rate irradiation with [³H]-labelled valine to selectively target hypoxic cells in a human colorectal cancer xenograft model
Acta Oncol, 57 (9), 1216-1224
DOI 10.1080/0284186X.2018.1457223, PubMed 29630428

Spasojevic M, Mariathasan AB, Goscinski M, Thorgersen EB, Solbakken AM, Gullestad HP, Ryder T, Flatmark K, Larsen SG (2018)
Vertical Rectus Abdominis Musculocutaneous Flap Repair Improves Perineal Wound Healing after Abdominoperineal Resection for Irradiated Locally Advanced Rectal Cancer
Ann Surg Oncol, 25 (5), 1357-1365
DOI 10.1245/s10434-018-6363-3, PubMed 29497909

Publications 2017

Andersson Y, Haavardtun SI, Davidson B, Dørum A, Fleten KG, Fodstad Ø, Flatmark K (2017)
MOC31PE immunotoxin - targeting peritoneal metastasis from epithelial ovarian cancer
Oncotarget, 8 (37), 61800-61809
DOI 10.18632/oncotarget.18694, PubMed 28977905

Bakke KM, Hole KH, Dueland S, Grøholt KK, Flatmark K, Ree AH, Seierstad T, Redalen KR (2017)
Diffusion-weighted magnetic resonance imaging of rectal cancer: tumour volume and perfusion fraction predict chemoradiotherapy response and survival
Acta Oncol, 56 (6), 813-818
DOI 10.1080/0284186X.2017.1287951, PubMed 28464745

Flem-Karlsen K, Tekle C, Andersson Y, Flatmark K, Fodstad Ø, Nunes-Xavier CE (2017)
Immunoregulatory protein B7-H3 promotes growth and decreases sensitivity to therapy in metastatic melanoma cells
Pigment Cell Melanoma Res, 30 (5), 467-476
DOI 10.1111/pcmr.12599, PubMed 28513992

Frøysnes IS, Andersson Y, Larsen SG, Davidson B, Øien JT, Olsen KH, Giercksky KE, Julsrud L, Fodstad Ø, Dueland S, Flatmark K (2017)
Novel Treatment with Intraperitoneal MOC31PE Immunotoxin in Colorectal Peritoneal Metastasis: Results From the ImmunoPeCa Phase 1 Trial
Ann Surg Oncol, 24 (7), 1916-1922
DOI 10.1245/s10434-017-5814-6, PubMed 28224367

Graudenzi A, Cava C, Bertoli G, Fromm B, Flatmark K, Mauri G, Castiglioni I (2017)
Pathway-based classification of breast cancer subtypes
Front Biosci (Landmark Ed), 22 (10), 1697-1712
DOI 10.2741/4566, PubMed 28410140

Ree AH, Russnes HG, Heinrich D, Dueland S, Boye K, Nygaard V, Silwal-Pandit L, Østrup O, Hovig E, Nygaard V, Rødland EA, Nakken S, Øien JT, Johansen C, Bergheim IR, Skarpeteig V, Sathermugathevan M, Sauer T, Lund-Iversen M, Beiske K, Nasser S, Julsrud L, Reisse CH, Ruud EA, Flørenes VA et al. (2017)
Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate
ESMO Open, 2 (2), e000158
DOI 10.1136/esmoopen-2017-000158, PubMed 28761742

Østrup O, Dagenborg VJ, Rødland EA, Skarpeteig V, Silwal-Pandit L, Grzyb K, Berstad AE, Fretland ÅA, Mælandsmo GM, Børresen-Dale AL, Ree AH, Edwin B, Nygaard V, Flatmark K (2017)
Molecular signatures reflecting microenvironmental metabolism and chemotherapy-induced immunogenic cell death in colorectal liver metastases
Oncotarget, 8 (44), 76290-76304
DOI 10.18632/oncotarget.19350, PubMed 29100312

Øverbye A, Holsæter AM, Markus F, Škalko-Basnet N, Iversen TG, Torgersen ML, Sønstevold T, Engebraaten O, Flatmark K, Mælandsmo GM, Skotland T, Sandvig K (2017)
Ceramide-containing liposomes with doxorubicin: time and cell-dependent effect of C6 and C12 ceramide
Oncotarget, 8 (44), 76921-76934
DOI 10.18632/oncotarget.20217, PubMed 29100358

Publications 2016

Boye K, Jacob H, Frikstad KA, Nesland JM, Maelandsmo GM, Dahl O, Nesbakken A, Flatmark K (2016)
Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a population-based series and a randomized phase III study on adjuvant chemotherapy
Cancer Med, 5 (8), 1840-9
DOI 10.1002/cam4.766, PubMed 27273130

Dueland S, Ree AH, Grøholt KK, Saelen MG, Folkvord S, Hole KH, Seierstad T, Larsen SG, Giercksky KE, Wiig JN, Boye K, Flatmark K (2016)
Oxaliplatin-containing Preoperative Therapy in Locally Advanced Rectal Cancer: Local Response, Toxicity and Long-term Outcome
Clin Oncol (R Coll Radiol), 28 (8), 532-9
DOI 10.1016/j.clon.2016.01.014, PubMed 26888115

Egeland EV, Flatmark K, Nesland JM, Flørenes VA, Mælandsmo GM, Boye K (2016)
Expression and clinical significance of Wee1 in colorectal cancer
Tumour Biol, 37 (9), 12133-12140
DOI 10.1007/s13277-016-5081-3, PubMed 27220319

Flatmark K, Høye E, Fromm B (2016)
microRNAs as cancer biomarkers
Scand J Clin Lab Invest Suppl, 245, S80-3
DOI 10.1080/00365513.2016.1210330, PubMed 27542003

Flatmark K, Saelen MG, Hole KH, Abrahamsen TW, Fleten KG, Hektoen HH, Redalen KR, Seierstad T, Dueland S, Ree AH (2016)
Individual tumor volume responses to short-course oxaliplatin-containing induction chemotherapy in locally advanced rectal cancer - Targeting the tumor for radiation sensitivity?
Radiother Oncol, 119 (3), 505-11
DOI 10.1016/j.radonc.2016.02.020, PubMed 26968754

Fleten KG, Bakke KM, Mælandsmo GM, Abildgaard A, Redalen KR, Flatmark K (2016)
Use of non-invasive imaging to monitor response to aflibercept treatment in murine models of colorectal cancer liver metastases
Clin Exp Metastasis, 34 (1), 51-62
DOI 10.1007/s10585-016-9829-3, PubMed 27812769

Frøysnes IS, Larsen SG, Spasojevic M, Dueland S, Flatmark K (2016)
Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis in Norway: Prognostic factors and oncologic outcome in a national patient cohort
J Surg Oncol, 114 (2), 222-7
DOI 10.1002/jso.24290, PubMed 27173150

Goscinski MA, Hole KH, Tønne E, Ryder T, Grøholt KK, Flatmark K (2016)
Fibromatosis in vertical rectus abdominis myocutaneous flap imitating tumor recurrence after surgery for locally advanced rectal cancer: case report
World J Surg Oncol, 14, 63
DOI 10.1186/s12957-016-0818-4, PubMed 26940557

Jonsson M, Ragnum HB, Julin CH, Yeramian A, Clancy T, Frikstad KM, Seierstad T, Stokke T, Matias-Guiu X, Ree AH, Flatmark K, Lyng H (2016)
Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition
Br J Cancer, 115 (8), 929-939
DOI 10.1038/bjc.2016.278, PubMed 27599042

Kalanxhi E, Hektoen HH, Meltzer S, Dueland S, Flatmark K, Ree AH (2016)
Circulating proteins in response to combined-modality therapy in rectal cancer identified by antibody array screening
BMC Cancer, 16, 536
DOI 10.1186/s12885-016-2601-x, PubMed 27461255

Kalanxhi E, Risberg K, Barua IS, Dueland S, Waagene S, Andersen SN, Pettersen SJ, Lindvall JM, Redalen KR, Flatmark K, Ree AH (2016)
Induction of Apoptosis in Intestinal Toxicity to a Histone Deacetylase Inhibitor in a Phase I Study with Pelvic Radiotherapy
Cancer Res Treat, 49 (2), 374-386
DOI 10.4143/crt.2016.080, PubMed 27488871

Meltzer S, Kalanxhi E, Hektoen HH, Dueland S, Flatmark K, Redalen KR, Ree AH (2016)
Systemic release of osteoprotegerin during oxaliplatin-containing induction chemotherapy and favorable systemic outcome of sequential radiotherapy in rectal cancer
Oncotarget, 7 (23), 34907-17
DOI 10.18632/oncotarget.8995, PubMed 27145458

Thorgersen EB, Goscinski MA, Spasojevic M, Solbakken AM, Mariathasan AB, Boye K, Larsen SG, Flatmark K (2016)
Deep Pelvic Surgical Site Infection After Radiotherapy and Surgery for Locally Advanced Rectal Cancer
Ann Surg Oncol, 24 (3), 721-728
DOI 10.1245/s10434-016-5621-5, PubMed 27766561

Publications 2015

Egeland EV, Boye K, Pettersen SJ, Haugen MH, Øyjord T, Malerød L, Flatmark K, Mælandsmo GM (2015)
Enrichment of nuclear S100A4 during G2/M in colorectal cancer cells: possible association with cyclin B1 and centrosomes
Clin Exp Metastasis, 32 (8), 755-67
DOI 10.1007/s10585-015-9742-1, PubMed 26349943

Fretland ÅA, Kazaryan AM, Bjørnbeth BA, Flatmark K, Andersen MH, Tønnessen TI, Bjørnelv GM, Fagerland MW, Kristiansen R, Øyri K, Edwin B (2015)
Open versus laparoscopic liver resection for colorectal liver metastases (the Oslo-CoMet Study): study protocol for a randomized controlled trial
Trials, 16, 73
DOI 10.1186/s13063-015-0577-5, PubMed 25872027

Fromm B, Billipp T, Peck LE, Johansen M, Tarver JE, King BL, Newcomb JM, Sempere LF, Flatmark K, Hovig E, Peterson KJ (2015)
A Uniform System for the Annotation of Vertebrate microRNA Genes and the Evolution of the Human microRNAome
Annu Rev Genet, 49, 213-42
DOI 10.1146/annurev-genet-120213-092023, PubMed 26473382

Hektoen HH, Flatmark K, Andersson Y, Dueland S, Redalen KR, Ree AH (2015)
Early increase in circulating carbonic anhydrase IX during neoadjuvant treatment predicts favourable outcome in locally advanced rectal cancer
BMC Cancer, 15, 543
DOI 10.1186/s12885-015-1557-6, PubMed 26205955

Hektoen HH, Ree AH, Redalen KR, Flatmark K (2015)
Sulfamate inhibitor S4 influences carbonic anhydrase IX ectodomain shedding in colorectal carcinoma cells
J Enzyme Inhib Med Chem, 31 (5), 779-86
DOI 10.3109/14756366.2015.1069286, PubMed 26244271

Lambrecht JR, Larsen SG, Reiertsen O, Vaktskjold A, Julsrud L, Flatmark K (2015)
Prophylactic mesh at end-colostomy construction reduces parastomal hernia rate: a randomized trial
Colorectal Dis, 17 (10), O191-7
DOI 10.1111/codi.13065, PubMed 26179984

Redalen KR, Sitter B, Bathen TF, Grøholt KK, Hole KH, Dueland S, Flatmark K, Ree AH, Seierstad T (2015)
High tumor glycine concentration is an adverse prognostic factor in locally advanced rectal cancer
Radiother Oncol, 118 (2), 393-8
DOI 10.1016/j.radonc.2015.11.031, PubMed 26705680

Ree AH, Flatmark K, Saelen MG, Folkvord S, Dueland S, Geisler J, Redalen KR (2015)
Tumor phosphatidylinositol 3-kinase signaling in therapy resistance and metastatic dissemination of rectal cancer: opportunities for signaling-adapted therapies
Crit Rev Oncol Hematol, 95 (1), 114-24
DOI 10.1016/j.critrevonc.2015.01.003, PubMed 25624177

Seierstad T, Hole KH, Grøholt KK, Dueland S, Ree AH, Flatmark K, Redalen KR (2015)
MRI volumetry for prediction of tumour response to neoadjuvant chemotherapy followed by chemoradiotherapy in locally advanced rectal cancer
Br J Radiol, 88 (1051), 20150097
DOI 10.1259/bjr.20150097, PubMed 25899892

Publications 2014

Haugen MH, Boye K, Nesland JM, Pettersen SJ, Egeland EV, Tamhane T, Brix K, Maelandsmo GM, Flatmark K (2014)
High expression of the cysteine proteinase legumain in colorectal cancer - implications for therapeutic targeting
Eur J Cancer, 51 (1), 9-17
DOI 10.1016/j.ejca.2014.10.020, PubMed 25466510

Ingebrigtsen VA, Boye K, Nesland JM, Nesbakken A, Flatmark K, Fodstad Ø (2014)
B7-H3 expression in colorectal cancer: associations with clinicopathological parameters and patient outcome
BMC Cancer, 14, 602
DOI 10.1186/1471-2407-14-602, PubMed 25139714

Pettersen EO, Ebbesen P, Gieling RG, Williams KJ, Dubois L, Lambin P, Ward C, Meehan J, Kunkler IH, Langdon SP, Ree AH, Flatmark K, Lyng H, Calzada MJ, Peso LD, Landazuri MO, Görlach A, Flamm H, Kieninger J, Urban G, Weltin A, Singleton DC, Haider S, Buffa FM, Harris AL et al. (2014)
Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium
J Enzyme Inhib Med Chem, 30 (5), 689-721
DOI 10.3109/14756366.2014.966704, PubMed 25347767

Ree AH, Meltzer S, Flatmark K, Dueland S, Kalanxhi E (2014)
Biomarkers of treatment toxicity in combined-modality cancer therapies with radiation and systemic drugs: study design, multiplex methods, molecular networks
Int J Mol Sci, 15 (12), 22835-56
DOI 10.3390/ijms151222835, PubMed 25501337

Ree AH, Saelen MG, Kalanxhi E, Østensen IH, Schee K, Røe K, Abrahamsen TW, Dueland S, Flatmark K (2014)
Biomarkers of histone deacetylase inhibitor activity in a phase 1 combined-modality study with radiotherapy
PLoS One, 9 (2), e89750
DOI 10.1371/journal.pone.0089750, PubMed 24587009

Wiiger MT, Bideli H, Fodstad O, Flatmark K, Andersson Y (2014)
The MOC31PE immunotoxin reduces cell migration and induces gene expression and cell death in ovarian cancer cells
J Ovarian Res, 7, 23
DOI 10.1186/1757-2215-7-23, PubMed 24528603

Publications 2013

Flatmark K, Guldvik IJ, Svensson H, Fleten KG, Flørenes VA, Reed W, Giercksky KE, Fodstad Ø, Andersson Y (2013)
Immunotoxin targeting EpCAM effectively inhibits peritoneal tumor growth in experimental models of mucinous peritoneal surface malignancies
Int J Cancer, 133 (6), 1497-506
DOI 10.1002/ijc.28158, PubMed 23494569

Friedman R, Boye K, Flatmark K (2013)
Molecular modelling and simulations in cancer research
Biochim Biophys Acta, 1836 (1), 1-14
DOI 10.1016/j.bbcan.2013.02.001, PubMed 23416097

Haugen MH, Johansen HT, Pettersen SJ, Solberg R, Brix K, Flatmark K, Maelandsmo GM (2013)
Nuclear legumain activity in colorectal cancer
PLoS One, 8 (1), e52980
DOI 10.1371/journal.pone.0052980, PubMed 23326369

Ragnum HB, Røe K, Holm R, Vlatkovic L, Nesland JM, Aarnes EK, Ree AH, Flatmark K, Seierstad T, Lilleby W, Lyng H (2013)
Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer
Int J Radiat Oncol Biol Phys, 87 (4), 753-60
DOI 10.1016/j.ijrobp.2013.07.023, PubMed 24035332

Rud AK, Borgen E, Mælandsmo GM, Flatmark K, Le H, Josefsen D, Solvoll I, Schirmer CB, Helland Å, Jørgensen L, Brustugun OT, Fodstad Ø, Boye K (2013)
Clinical significance of disseminated tumour cells in non-small cell lung cancer
Br J Cancer, 109 (5), 1264-70
DOI 10.1038/bjc.2013.450, PubMed 23942067

Schee K, Lorenz S, Worren MM, Günther CC, Holden M, Hovig E, Fodstad O, Meza-Zepeda LA, Flatmark K (2013)
Deep Sequencing the MicroRNA Transcriptome in Colorectal Cancer
PLoS One, 8 (6), e66165
DOI 10.1371/journal.pone.0066165, PubMed 23824282

Sørensen O, Andersen AM, Kristian A, Giercksky KE, Flatmark K (2013)
Impact of hyperthermia on pharmacokinetics of intraperitoneal mitomycin C in rats investigated by microdialysis
J Surg Oncol, 109 (6), 521-6
DOI 10.1002/jso.23527, PubMed 24347444

Zhai H, Fesler A, Schee K, Fodstad O, Flatmark K, Ju J (2013)
Clinical significance of long intergenic noncoding RNA-p21 in colorectal cancer
Clin Colorectal Cancer, 12 (4), 261-6
DOI 10.1016/j.clcc.2013.06.003, PubMed 24012455

Publications 2012

Boye K, Nesland JM, Sandstad B, Haugland Haugen M, Mælandsmo GM, Flatmark K (2012)
EMMPRIN is associated with S100A4 and predicts patient outcome in colorectal cancer
Br J Cancer, 107 (4), 667-74
DOI 10.1038/bjc.2012.293, PubMed 22782346

Brusegard K, Stavnes HT, Nymoen DA, Flatmark K, Trope CG, Davidson B (2012)
Rab25 is overexpressed in Müllerian serous carcinoma compared to malignant mesothelioma
Virchows Arch, 460 (2), 193-202
DOI 10.1007/s00428-011-1191-x, PubMed 22249560

Ingebrigtsen VA, Boye K, Tekle C, Nesland JM, Flatmark K, Fodstad O (2012)
B7-H3 expression in colorectal cancer: nuclear localization strongly predicts poor outcome in colon cancer
Int J Cancer, 131 (11), 2528-36
DOI 10.1002/ijc.27566, PubMed 22473715

Ree AH, Kristensen AT, Saelen MG, de Wijn R, Edvardsen H, Jovanovic J, Abrahamsen TW, Dueland S, Flatmark K (2012)
Tumor phosphatidylinositol-3-kinase signaling and development of metastatic disease in locally advanced rectal cancer
PLoS One, 7 (11), e50806
DOI 10.1371/journal.pone.0050806, PubMed 23226389

Saelen MG, Ree AH, Kristian A, Fleten KG, Furre T, Hektoen HH, Flatmark K (2012)
Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma
Radiat Oncol, 7, 165
DOI 10.1186/1748-717X-7-165, PubMed 23017053

Schee K, Boye K, Abrahamsen TW, Fodstad Ø, Flatmark K (2012)
Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer
BMC Cancer, 12, 505
DOI 10.1186/1471-2407-12-505, PubMed 23121918

Schee K, Flatmark K, Holm R, Boye K, Paus E (2012)
Investigation of nonspecific cross-reacting antigen 2 as a prognostic biomarker in bone marrow plasma from colorectal cancer patients (vol 33, pg 73, 2012)
Tumor Biol., 33 (4), 1263-1264
DOI 10.1007/s13277-012-0407-2

Sørensen O, Flatmark K, Reed W, Wiig JN, Dueland S, Giercksky KE, Larsen SG (2012)
Evaluation of complete cytoreductive surgery and two intraperitoneal chemotherapy techniques in Pseudomyxoma peritonei
Eur J Surg Oncol, 38 (10), 969-76
DOI 10.1016/j.ejso.2012.06.552, PubMed 22763244

Publications 2011

Bratland A, Dueland S, Hollywood D, Flatmark K, Ree AH (2011)
Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy
Radiat Oncol, 6, 33
DOI 10.1186/1748-717X-6-33, PubMed 21473790

Flatmark K, Borgen E, Nesland JM, Rasmussen H, Johannessen HO, Bukholm I, Rosales R, Hårklau L, Jacobsen HJ, Sandstad B, Boye K, Fodstad Ø (2011)
Disseminated tumour cells as a prognostic biomarker in colorectal cancer
Br J Cancer, 104 (9), 1434-9
DOI 10.1038/bjc.2011.97, PubMed 21448171

Saelen MG, Flatmark K, Folkvord S, de Wijn R, Rasmussen H, Fodstad Ø, Ree AH (2011)
Tumor kinase activity in locally advanced rectal cancer: angiogenic signaling and early systemic dissemination
Angiogenesis, 14 (4), 481-9
DOI 10.1007/s10456-011-9231-3, PubMed 21833622

Schee K, Flatmark K, Holm R, Boye K, Paus E (2011)
Investigation of nonspecific cross-reacting antigen 2 as a prognostic biomarker in bone marrow plasma from colorectal cancer patients
Tumour Biol, 33 (1), 73-83
DOI 10.1007/s13277-011-0247-5, PubMed 22006279

Wiig JN, Larsen SG, Dueland S, Flatmark K, Giercksky KE (2011)
Salvage surgery for locally recurrent rectal cancer: total mesorectal excision during the primary operation does not influence the outcome
Colorectal Dis, 13 (5), 506-11
DOI 10.1111/j.1463-1318.2010.02256.x, PubMed 20236148

Publications 2010

Berge G, Costea DE, Berg M, Rasmussen H, Grotterød I, Lothe RA, Mælandsmo GM, Flatmark K (2010)
Coexpression and nuclear colocalization of metastasis-promoting protein S100A4 and p53 without mutual regulation in colorectal carcinoma
Amino Acids, 41 (4), 875-84
DOI 10.1007/s00726-010-0514-6, PubMed 20191297

Boye K, Nesland JM, Sandstad B, Mælandsmo GM, Flatmark K (2010)
Nuclear S100A4 is a novel prognostic marker in colorectal cancer
Eur J Cancer, 46 (16), 2919-25
DOI 10.1016/j.ejca.2010.07.013, PubMed 20719498

Flatmark K, Davidson B, Kristian A, Stavnes HT, Førsund M, Reed W (2010)
Exploring the peritoneal surface malignancy phenotype--a pilot immunohistochemical study of human pseudomyxoma peritonei and derived animal models
Hum Pathol, 41 (8), 1109-19
DOI 10.1016/j.humpath.2009.12.013, PubMed 20338618

Flatmark K, Ree AH (2010)
Radiosensitizing drugs: lessons to be learned from the oxaliplatin story
J Clin Oncol, 28 (29), e577-8; author reply e581-3
DOI 10.1200/JCO.2010.30.0921, PubMed 20733124

Folkvord S, Flatmark K, Dueland S, de Wijn R, Grøholt KK, Hole KH, Nesland JM, Ruijtenbeek R, Boender PJ, Johansen M, Giercksky KE, Ree AH (2010)
Prediction of response to preoperative chemoradiotherapy in rectal cancer by multiplex kinase activity profiling
Int J Radiat Oncol Biol Phys, 78 (2), 555-62
DOI 10.1016/j.ijrobp.2010.04.036, PubMed 20675069

Paus E, Haugen MH, Olsen KH, Flatmark K, Maelandsmo GM, Nilsson O, Röijer E, Lundin M, Fermér C, Samsonova M, Lebedin Y, Stigbrand T (2010)
TD-11 workshop report: characterization of monoclonal antibodies to S100 proteins
Tumour Biol, 32 (1), 1-12
DOI 10.1007/s13277-010-0073-1, PubMed 20652782

Ree AH, Dueland S, Folkvord S, Hole KH, Seierstad T, Johansen M, Abrahamsen TW, Flatmark K (2010)
Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study
Lancet Oncol, 11 (5), 459-64
DOI 10.1016/S1470-2045(10)70058-9, PubMed 20378407

Schee K, Fodstad Ø, Flatmark K (2010)
MicroRNAs as biomarkers in colorectal cancer
Am J Pathol, 177 (4), 1592-9
DOI 10.2353/ajpath.2010.100024, PubMed 20829435

Sørensen O, Andersen A, Olsen H, Alexandr K, Ekstrøm PO, Giercksky KE, Flatmark K (2010)
Validation and use of microdialysis for determination of pharmacokinetic properties of the chemotherapeutic agent mitomycin C - an experimental study
BMC Cancer, 10, 469
DOI 10.1186/1471-2407-10-469, PubMed 20809961

Publications 2009

Folkvord S, Ree AH, Furre T, Halvorsen T, Flatmark K (2009)
Radiosensitization by SAHA in experimental colorectal carcinoma models-in vivo effects and relevance of histone acetylation status
Int J Radiat Oncol Biol Phys, 74 (2), 546-52
DOI 10.1016/j.ijrobp.2009.01.068, PubMed 19427556

Maelandsmo GM, Flørenes VA, Nguyen MT, Flatmark K, Davidson B (2009)
Different expression and clinical role of S100A4 in serous ovarian carcinoma at different anatomic sites
Tumour Biol, 30 (1), 15-25
DOI 10.1159/000199447, PubMed 19194111

Seierstad T, Hole KH, Saelen E, Ree AH, Flatmark K, Malinen E (2009)
MR-guided simultaneous integrated boost in preoperative radiotherapy of locally advanced rectal cancer following neoadjuvant chemotherapy
Radiother Oncol, 93 (2), 279-84
DOI 10.1016/j.radonc.2009.08.046, PubMed 19800704

Publications 2008

Brunsvig PF, Flatmark K, Aamdal S, Høifødt H, Le H, Jakobsen E, Sandstad B, Fodstad O (2008)
Bone marrow micrometastases in advanced stage non-small cell lung carcinoma patients
Lung Cancer, 61 (2), 170-6
DOI 10.1016/j.lungcan.2007.12.018, PubMed 18261824

Haugen MH, Flatmark K, Mikalsen SO, Malandsmo GM (2008)
The metastasis-associated protein S100A4 exists in several charged variants suggesting the presence of posttranslational modifications
BMC Cancer, 8, 172
DOI 10.1186/1471-2407-8-172, PubMed 18554396

Ree AH, Folkvord S, Flatmark K (2008)
HDAC2 deficiency and histone acetylation
Nat Genet, 40 (7), 812-3; author reply 813
DOI 10.1038/ng0708-812, PubMed 18583969

Seierstad T, Røe K, Sitter B, Halgunset J, Flatmark K, Ree AH, Olsen DR, Gribbestad IS, Bathen TF (2008)
Principal component analysis for the comparison of metabolic profiles from human rectal cancer biopsies and colorectal xenografts using high-resolution magic angle spinning 1H magnetic resonance spectroscopy
Mol Cancer, 7, 33
DOI 10.1186/1476-4598-7-33, PubMed 18439252

Publications 2007

Flatmark K, Reed W, Halvorsen T, Sørensen O, Wiig JN, Larsen SG, Fodstad Ø, Giercksky KE (2007)
Pseudomyxoma peritonei--two novel orthotopic mouse models portray the PMCA-I histopathologic subtype
BMC Cancer, 7, 116
DOI 10.1186/1471-2407-7-116, PubMed 17603904

Folkvord S, Flatmark K, Seierstad T, Røe K, Rasmussen H, Ree AH (2007)
Inhibitory effects of oxaliplatin in experimental radiation treatment of colorectal carcinoma: does oxaliplatin improve 5-fluorouracil-dependent radiosensitivity?
Radiother Oncol, 86 (3), 428-34
DOI 10.1016/j.radonc.2007.10.012, PubMed 18006097

Seierstad T, Folkvord S, Røe K, Flatmark K, Skretting A, Olsen DR (2007)
Early changes in apparent diffusion coefficient predict the quantitative antitumoral activity of capecitabine, oxaliplatin, and irradiation in HT29 xenografts in athymic nude mice
Neoplasia, 9 (5), 392-400
DOI 10.1593/neo.07154, PubMed 17534444

Publications 2006

Flatmark K, Nome RV, Folkvord S, Bratland A, Rasmussen H, Ellefsen MS, Fodstad Ø, Ree AH (2006)
Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition
Radiat Oncol, 1, 25
DOI 10.1186/1748-717X-1-25, PubMed 16887021

Ree AH, Stokke T, Bratland A, Patzke S, Nome RV, Folkvord S, Meza-Zepeda LA, Flatmark K, Fodstad O, Andersson Y (2006)
DNA damage responses in cell cycle G2 phase and mitosis--tracking and targeting
Anticancer Res, 26 (3A), 1909-16
PubMed 16827124

Publications 2005

Bjørnland K, Flatmark K, Pettersen S, Aaasen AO, Fodstad O, Maelandsmo GM (2005)
Matrix metalloproteinases participate in osteosarcoma invasion
J Surg Res, 127 (2), 151-6
DOI 10.1016/j.jss.2004.12.016, PubMed 16083752

Publications 2004

Flatmark K (2004)
Studies of colorectal cancer metastasis
In Series of dissertations submitted to the Faculty of Medicine, University of Oslo, Unipub, Oslo, no. 200, 1 b. (flere pag.)
BIBSYS 041949617, ISBN 82-8072-144-4

Flatmark K, Maelandsmo GM, Martinsen M, Rasmussen H, Fodstad Ø (2004)
Twelve colorectal cancer cell lines exhibit highly variable growth and metastatic capacities in an orthotopic model in nude mice
Eur J Cancer, 40 (10), 1593-8
DOI 10.1016/j.ejca.2004.02.023, PubMed 15196545

Flatmark K, Maelandsmo GM, Mikalsen SO, Nustad K, Varaas T, Rasmussen H, Meling GI, Fodstad Ø, Paus E (2004)
Immunofluorometric assay for the metastasis-related protein S100A4: release of S100A4 from normal blood cells prohibits the use of S100A4 as a tumor marker in plasma and serum
Tumour Biol, 25 (1-2), 31-40
DOI 10.1159/000077721, PubMed 15192310

Publications 2003

Bjørnland K, Flatmark K, Mala T, Mathisen O, Bakka A, Aasen AO, Bergan A, Søreide O, Fodstad O (2003)
Detection of disseminated tumour cells in bone marrow of patients with isolated liver metastases from colorectal cancer
J Surg Oncol, 82 (4), 224-7
DOI 10.1002/jso.10223, PubMed 12672004

Flatmark K, Pedersen KB, Nesland JM, Rasmussen H, Aamodt G, Mikalsen SO, Bjørnland K, Fodstad Ø, Maelandsmo GM (2003)
Nuclear localization of the metastasis-related protein S100A4 correlates with tumour stage in colorectal cancer
J Pathol, 200 (5), 589-95
DOI 10.1002/path.1381, PubMed 12898594

Publications 2002

Flatmark K, Bjørnland K, Johannessen HO, Hegstad E, Rosales R, Hårklau L, Solhaug JH, Faye RS, Søreide O, Fodstad Ø, Study Group for Micrometastases in BM in Colorectal Cancer (2002)
Immunomagnetic detection of micrometastatic cells in bone marrow of colorectal cancer patients
Clin Cancer Res, 8 (2), 444-9
PubMed 11839662

Publications 2000

Flatmark K, Nilsen BH (2000)
[Postoperative wound infections in elective colorectal surgery]
Tidsskr Nor Laegeforen, 120 (23), 2761-3
PubMed 11107920